证券代码：688075 证券简称：安旭生物 公告编号：2025-015 ● 相关日期 ■ 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025年5月22日的2024年年度股东大会审议通过。 2.分派对象： 杭州安旭生物科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.8元 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 本次利润分配以方案实施前的公司总股本127,082,805股为基数，每股派发现金红利0.8元（含税），共 计派发现金红利101,666,244.00元。 三、相关日期 ■ 四、分配实施办法 1.实施办法 部分无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统向股权登记日上海证券交易 所收市后登记在册并在上海证券交易所各会员办理了指定交易的股东派发。已办理指定交易的投资者可 于红利发放日在其指定 ...

Core Points - The company announced a cash dividend distribution of 0.8 RMB per share, totaling 101,666,244 RMB based on a total share capital of 127,082,805 shares [1] - The dividend distribution plan was approved at the annual general meeting held on May 22, 2025 [1] - The cash dividend will be distributed to shareholders registered by the end of the trading day on the record date [1] Dividend Distribution Details - The cash dividend of 0.8 RMB per share is inclusive of tax [1] - The distribution will be managed by China Securities Depository and Clearing Corporation Limited, Shanghai Branch [1] - Shareholders who have not completed designated transactions will have their dividends held by the clearing company until the transactions are completed [1] Tax Implications - For individual shareholders holding unrestricted shares for over one year, the dividend income is exempt from individual income tax [3] - For shares held for less than one year, the tax treatment varies: 20% tax for holdings of one month or less, and 10% tax for holdings between one month and one year [3] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, resulting in a net dividend of 0.72 RMB per share [5] - Hong Kong investors will also receive a net dividend of 0.72 RMB per share after a 10% tax withholding [5]

证券代码：688075 证券简称：安旭生物 公告编号：2025-015 杭州安旭生物科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.8元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/17 | 2025/7/18 | 2025/7/18 | 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 22 日的2024年年度股东大会审议通过。 二、分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本127,082,805股为基数，每股派发现 金红利0.8元（含税），共计派发现金红利101,666,244.00元。 三、相关日期 | 股权登记日 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Anxu Biotech, indicating a decline in revenue and profit while comparing its valuation metrics to industry averages [1][2] - Anxu Biotech's closing stock price is 39.22 yuan, with a rolling PE ratio of 31.92, marking a new low in 22 days, and a total market capitalization of 4.984 billion yuan [1] - The company ranks 70th in the medical device industry, which has an average PE ratio of 51.58 and a median of 37.46 [1][2] Group 2 - As of the first quarter of 2025, six institutions hold shares in Anxu Biotech, with a total of 50.3836 million shares valued at 1.998 billion yuan [1] - Anxu Biotech specializes in the research, production, and sales of POCT reagents and instruments, having received multiple certifications including EU CE, Canadian, and Australian certifications [1] - The latest financial report for the first quarter of 2025 shows a revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.0296 million yuan, down 51.52% year-on-year, with a gross margin of 42.32% [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 杭州安旭生物科技股份有限公司（以下简称"安旭生物"或"公司"）董事会首次公开发行股票募集资金按 照相关法律、法规和规范性文件的规定在银行开立了募集资金专项账户。近日，公司办理完成部分募集 资金专用账户的注销手续，现将具体情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会于2021年9月28日出具的《关于同意杭州安旭生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕3138号），公司获准向社会公开发行人民币普通股 15,333,400股，每股发行价格为人民币78.28元，募集资金总额为120,029.86万元；扣除承销及保荐费 用、发行登记费以及其他交易费用共计14,445.23万元（不含增值税金额）后，募集资金净额为 105,584.63万元，上述资金已全部到位，经信永中和会计师事务所（特殊普通合伙）审验并于2021年11 月12日出具了"XYZH/2021HZAA10537"《验资报告》。 募集资金到账后，已全部存放于经公司董事会 批准开 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-014 杭州安旭生物科技股份有限公司 关于部分募集资金账户注销的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安旭生物科技股份有限公司（以下简称"安旭生物"或"公司"）董事会首次 公开发行股票募集资金按照相关法律、法规和规范性文件的规定在银行开立了募集资 金专项账户。近日，公司办理完成部分募集资金专用账户的注销手续，现将具体情况 公告如下： 一、 募集资金基本情况 根据中国证券监督管理委员会于 2021 年 9 月 28 日出具的《关于同意杭州安旭生 物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3138 号），公 司获准向社会公开发行人民币普通股 15,333,400 股，每股发行价格为人民币 78.28 元， 募集资金总额为 120,029.86 万元；扣除承销及保荐费用、发行登记费以及其他交易费 用共计 14,445.23 万元（不含增值税金额）后，募集资金净额为 105,584.63 万元，上述 资金已全部到位，经信永 ...

Company Overview - Anxu Bio focuses on the research, development, production, and sales of POCT reagents and instruments [1] - The company has been recognized as a "Zhejiang Province Intellectual Property Demonstration Enterprise" and a "National Intellectual Property Advantage Enterprise" [1] - As of 2024, Anxu Bio has obtained a total of 305 authorized patents, including 43 invention patents [1] Financial Performance - For Q1 2025, Anxu Bio reported a revenue of 115 million yuan, a year-on-year decrease of 10.90% [1] - The net profit for the same period was approximately 34.03 million yuan, reflecting a year-on-year decline of 51.52% [1] - The gross profit margin for the company stood at 42.32% [1] Market Position - Anxu Bio's current price-to-earnings (PE) ratio is 30.77, compared to the industry average of 49.12 and the industry median of 36.07 [2] - The company's total market capitalization is 4.805 billion yuan [1][2] - As of Q1 2025, six institutions hold shares in Anxu Bio, with a total holding of approximately 50.38 million shares valued at 1.998 billion yuan [1]

6月18日，安旭生物今日收盘37.48元，下跌1.13%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到30.51倍，总市值47.63亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.10倍，行业中值36.43倍，安旭生物排 名第69位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13安旭生物30.5124.770.9147.63亿行业平均 49.1047.114.54105.10亿行业中值36.4336.872.3948.92亿1英科医疗9.5610.310.85151.03亿2九安医疗 10.1210.230.80170.79亿3新华医疗14.2213.181.1691.18亿4振德医疗14.6413.800.9353.16亿5康德莱 14.7414.751.2231.75亿6奥美医疗14.8614.571.5353.70亿7山东药玻15.7315.781.81148.78亿8九强生物 15.7414.641.9377.95亿9维力医疗15.7716.391.8535.96亿10奥泰生物16.0716.951.3051.26亿11安杰思 17.3817.582. ...

Core Viewpoint - The report indicates that Hangzhou Anxu Biotechnology Co., Ltd. has maintained a sound governance structure and effective internal controls during the continuous supervision period, with no violations in fundraising, related transactions, or operational status [1][5]. Group 1: Company Governance and Internal Control - The company’s articles of association and governance systems are complete and effectively executed [2]. - The board of directors, supervisors, and senior management fulfill their responsibilities as required [2]. - Internal control systems are effectively implemented [2]. Group 2: Information Disclosure - The company has fulfilled its information disclosure obligations accurately and completely, with no false records or misleading statements [2][5]. Group 3: Independence and Related Party Transactions - The company maintains independence in assets, personnel, finance, and business, with no violations regarding the occupation of company funds by related parties [3][4]. Group 4: Fundraising and Usage - The company has adhered to fundraising management regulations, with funds stored in dedicated accounts and no unauthorized changes in usage [3][4]. Group 5: Related Transactions and Investments - There are no violations regarding external guarantees, related transactions, or significant external investments during the supervision period [4][5]. Group 6: Operational Status - The company’s business model and structure have not undergone significant adverse changes, and its operational status remains normal [4][5]. Group 7: Compliance and Recommendations - The company is advised to continue improving its governance structure and ensure timely information disclosure while managing fundraising effectively [5].

民生证券股份有限公司 关于杭州安旭生物科技股份有限公司 2024 年度持续督导工作现场检查报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法律、 法规的规定，民生证券股份有限公司（以下简称"保荐机构"）作为杭州安旭 生物科技股份有限公司（以下简称"安旭生物"或"公司"）首次公开发行股 票并在科创板上市的保荐机构，对公司 2024 年度（以下简称"本持续督导 期"）的规范运作情况进行了现场检查，现就有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐机构 民生证券股份有限公司 （二）保荐代表人 孙闽、朱仙掌 （三）现场检查时间 2025 年 5 月 19 日 （四）现场检查人员 朱仙掌 （五）现场检查内容 公司治理、内部控制，信息披露，独立性以及与控股股东、实际控制人及 其他关联方资金往来情况，募集资金使用，关联交易、对外担保、重大对外投 资，经营状况等。 （六）现场检查手段 1、查看公司主要生产经营场所，对公司相关人员进行访谈； 1 2、查阅本持续督导期间公司召开的历次三会文件； 3、查阅本持续督导期间公司的信 ...